In brief
In a recent shakeup at the Food and Drug Administration, Dr. Tracy Beth Hoeg was removed from her role as the acting director of the agency's drug program. Her removal follows the resignation of FDA Commissioner Marty Makary and other leadership changes, highlighting growing political tensions over vaccine policies and drug safety. Dr. Mike Davis, previously deputy director, will replace Hoeg, who had previously raised concerns about COVID-19 vaccinations and antidepressant safety. The FDA's leadership transition reflects ongoing scrutiny from political allies of former President Trump and criticisms from various health advocates.
In a notable shift in operations, the Food and Drug Administration (FDA) has announced the removal of Dr. Tracy Beth Hoeg, an official prominently involved in assessing the safety of antidepressants and COVID-19 vaccines. Her departure was communicated via an internal email that also disclosed her replacement by Dr. Mike Davis, who previously held the position of deputy director.
Dr. Hoeg publicly stated on social media that she was 'fired,' expressing gratitude for her tenure and asserting that she left without any regrets.
This change comes amid a flurry of transitions at the FDA, which has seen high-profile resignations, including that of FDA Commissioner Marty Makary just earlier this week. Notable figures such as Dr. Vinay Prasad, the agency's vaccine and biotech chief, also stepped down under increased scrutiny from pharmaceutical companies, patients, and investors.
In addition to Hoeg's exit, the FDA has appointed Karim Mikhail as the acting director of the vaccines center. Mikhail is a veteran pharmaceutical executive brought in by Makary last spring.
Hoeg's removal is part of a broader management overhaul at the FDA, which has faced mounting pressure from groups affiliated with former President Trump, including anti-abortion activists and vaping lobbyists. Their grievances predominantly revolve around the agency's regulatory direction.
Having overseen the FDA’s drug program since December, Hoeg was a controversial figure whose inquiries into drug safety reflected her interests as a public health scientist. Prior to joining the FDA, she gained notoriety during the pandemic for her criticisms of various public health measures related to COVID-19.
Her analysis led to significant debates over the safety of vaccines, including facilitating discussions on potential links between childhood vaccinations and serious health risks, claims that were generally discredited by health officials.
As her tenure at the agency continues to draw attention, questions remain surrounding the direction of the FDA and its ongoing leadership challenges.
